Search

Your search keyword '"Heijerman, Harry"' showing total 414 results

Search Constraints

Start Over You searched for: Author "Heijerman, Harry" Remove constraint Author: "Heijerman, Harry"
414 results on '"Heijerman, Harry"'

Search Results

1. Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study

4. Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials

12. Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy

13. Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation

14. Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations

17. ECFS best practice guidelines: the 2018 revision

20. Radiological and long‐term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease

23. Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials

24. Development and validation of a novel personalized electronic patient-reported outcome measure to assess quality of life (Q-LIFE): a prospective observational study in people with Cystic Fibrosis

27. Radiological and long-term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease

28. Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor

29. Development and outcomes of a patient driven cystic fibrosis quality of care improvement project

30. Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor

32. Measuring cystic fibrosis drug responses in organoids derived from 2D differentiated nasal epithelia

35. Measuring cystic fibrosis drug responses in organoids derived from 2D differentiated nasal epithelia

36. Measuring cystic fibrosis drug responses in organoids derived from 2D differentiated nasal epithelia

37. Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor

38. Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis

39. Measuring cystic fibrosis drug responses in organoids derived from 2D differentiated nasal epithelia

40. The effect of maintenance azithromycin on radiological features in patients with bronchiectasis - Analysis from the BAT randomized controlled trial

41. Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation

42. The relation between psychological distress and medication adherence in lung transplant candidates and recipients: A cross-sectional study

44. sj-docx-1-tar-10.1177_17534666211070143 ��� Supplemental material for Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation

Catalog

Books, media, physical & digital resources